GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Debt-to-Revenue

Sino Biopharmaceutical (FRA:SMZ1) Debt-to-Revenue : 0.38 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sino Biopharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €1,356 Mil. Sino Biopharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €133 Mil. Sino Biopharmaceutical's annualized Revenue for the quarter that ended in Jun. 2023 was €3,938 Mil. Sino Biopharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.38.


Sino Biopharmaceutical Debt-to-Revenue Historical Data

The historical data trend for Sino Biopharmaceutical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Debt-to-Revenue Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.60 0.45 0.49 0.48

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.40 0.52 0.38 0.58

Competitive Comparison of Sino Biopharmaceutical's Debt-to-Revenue

For the Biotechnology subindustry, Sino Biopharmaceutical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Debt-to-Revenue falls into.



Sino Biopharmaceutical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sino Biopharmaceutical's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1316.652 + 576.569) / 3896.999
=0.49

Sino Biopharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1356.228 + 132.923) / 3937.974
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Sino Biopharmaceutical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (FRA:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines